US RE50,642 E1
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Isan Chen, San Diego, CA (US)
Assigned to Aragon Pharmaceuticals, Inc., Los Angeles, CA (US)
Filed by Aragon Pharmaceuticals, Inc., Los Angeles, CA (US)
Filed on Aug. 26, 2022, as Appl. No. 17/896,658.
Application 17/896,658 is a continuation of application No. 16/998,683, filed on Aug. 20, 2020, granted, now RE49353.
Application 15/851,444 is a continuation of application No. 14/034,460, filed on Sep. 23, 2013, granted, now 9,884,054, issued on Feb. 6, 2018.
Application 16/998,683 is a reissue of application No. 15/851,444, filed on Dec. 21, 2017, granted, now 10,052,314, issued on Aug. 21, 2018.
Application 17/896,658 is a reissue of application No. 15/851,444, filed on Dec. 21, 2017, granted, now 10,052,314, issued on Aug. 21, 2018.
Claims priority of provisional application 61/705,900, filed on Sep. 26, 2012.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4439 (2006.01); A61K 31/00 (2006.01); A61K 31/4166 (2006.01)
CPC A61K 31/4439 (2013.01) [A61K 31/00 (2013.01); A61K 31/4166 (2013.01)] 31 Claims
 
[ 26. A method of treating non-metastatic castration-resistant prostate cancer in a male human comprising administering a therapeutically effective amount of an anti-androgen to a male human with a non-metastatic castration-resistant prostate cancer;
wherein the anti-androgen is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro [3.4]oct-5-yl]-2-fluoro-N-methylbenzamide;
wherein the anti-androgen is administered in an amount of about 180 mg per day or 120 mg per day;
and wherein said method further comprises administering a gonadotropin releasing hormone (GnRH) agonist.]